Lantern Pharma to Current Constructive Preclinical Knowledge on the Efficacy of LP-284 for Mantle Cell Lymphoma on the Society of Hematologic Oncology Annual Assembly

DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN), a medical stage biopharmaceutical firm utilizing its proprietary RADR® synthetic intelligence (“A.I.”) and machine studying (“M.L.”) platform to rework the fee, tempo, and timeline of oncology drug discovery and growth, right this moment introduced that it’ll current preclinical knowledge on the efficiency of Lantern’s drug candidate LP-284 for mantle cell lymphoma (MCL) and several other different non-Hodgkin’s lymphomas on the Society of Hematologic Oncology (SOHO) Tenth Annual Assembly, Sept. 28 – Oct. 1, 2022, in Houston, TX.

LP-284 is a subsequent technology acylfulvene that has a synthetically deadly mechanism of motion in cancers with impaired DNA injury restore (DDR) pathway genes. In Lantern’s preclinical testing, LP-284 has proven in vitro and in vivo anti-tumor efficiency throughout a variety of non-Hodgkin’s B-cell lymphomas. Of the lymphomas examined up to now, LP-284 had the best efficiency in opposition to quite a few MCL cell traces, together with these which can be immune to the standard-of-care (SOC) brokers Ibrutinib and Bortezomib. Within the US, MCL is estimated to be recognized in round 4,500 sufferers annually and represents an approximate $200 million in annual remedy gross sales.

Lantern’s LP-284 program has been accelerated and de-risked utilizing A.I. insights and organic modeling powered by RADR®. Lantern has been capable of advance LP-284 from preliminary RADR® insights concerning anti-cancer exercise and potential mechanisms of motion in hematological cancers, to number of particular subtypes of lymphomas with superior response, to late stage IND enabling research and preliminary design of first in human medical trials in lower than 2 years. Lantern is planning on an IND submission for LP-284 in Q1 2023 and anticipates launching a Part 1 medical trial in Q2 2023.

Particulars of the poster presentation are listed under and will be discovered on the SOHO web site. A full model of the poster will probably be out there on Lantern’s web site on October 3, 2022.

Title: LP-284 – A Extremely Potent Small Molecule Concentrating on Mantle Cell Lymphoma

Date and Time: September 28, 2022, 5:05pm CT

Poster Quantity: MCL-319

Presenter: Jianli Zhou, Lantern Pharma

About Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical firm leveraging its proprietary RADR® A.I. and machine studying platform to find biomarker signatures that determine sufferers most probably to answer its pipeline of genomically-targeted therapeutics. Lantern is at the moment creating 4 drug candidates and an ADC program throughout 9 disclosed tumor targets, together with two section 2 packages. By concentrating on medication to sufferers whose genomic profile identifies them as having the best likelihood of benefiting from the drug, Lantern’s method represents the potential to ship best-in-class outcomes.

Please discover extra data at:

Web site:


Twitter: @lanternpharma

Ahead-looking Statements

This press launch accommodates forward-looking statements inside the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended. These forward-looking statements embrace, amongst different issues, statements regarding: future occasions or our future monetary efficiency; the potential benefits of our RADR® platform in figuring out drug candidates and affected person populations which can be probably to answer a drug candidate; our strategic plans to advance the event of our drug candidates and antibody drug conjugate (ADC) growth program; estimates concerning the event timing for our drug candidates and ADC growth program; expectations and estimates concerning medical trial timing and affected person enrollment; our analysis and growth efforts of our inside drug discovery packages and the utilization of our RADR® platform to streamline the drug growth course of; our intention to leverage synthetic intelligence, machine studying and genomic knowledge to streamline and remodel the tempo, threat and price of oncology drug discovery and growth and to determine affected person populations that may probably reply to a drug candidate; estimates concerning affected person populations, potential markets and potential market sizes; gross sales estimates for our drug candidates and our plans to find and develop drug candidates and to maximise their business potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that aren’t statements of historic reality (together with, with out limitation, statements that use phrases equivalent to “anticipate,” “consider,” “ponder,” “might,” “estimate,” “anticipate,” “intend,” “search,” “could,” “would possibly,” “plan,” “potential,” “predict,” “challenge,” “goal,” “goal,” “goal,” “upcoming,” “ought to,” “will,” “would,” or the unfavorable of those phrases or different comparable expressions) ought to be thought of forward-looking statements. There are a selection of essential components that would trigger our precise outcomes to vary materially from these indicated by the forward-looking statements, equivalent to (i) the affect of the COVID-19 pandemic, (ii) the chance that our analysis and the analysis of our collaborators will not be profitable, (iii) the chance that none of our product candidates has obtained FDA advertising approval, and we could not be capable of efficiently provoke, conduct, or conclude medical testing for or acquire advertising approval for our product candidates, (iv) the chance that no drug product primarily based on our proprietary RADR® A.I. platform has obtained FDA advertising approval or in any other case been integrated right into a business product, and (v) these different components set forth within the Danger Components part in our Annual Report on Kind 10-Okay for the yr ended December 31, 2021, filed with the Securities and Alternate Fee on March 10, 2022. Chances are you’ll entry our Annual Report on Kind 10-Okay for the yr ended December 31, 2021 below the investor SEC filings tab of our web site at or on the SEC’s web site at Given these dangers and uncertainties, we may give no assurances that our forward-looking statements will show to be correct, or that another outcomes or occasions projected or contemplated by our forward-looking statements will actually happen, and we warning traders to not place undue reliance on these statements. All forward-looking statements on this press launch signify our judgment as of the date hereof, and, besides as in any other case required by regulation, we disclaim any obligation to replace any forward-looking statements to adapt the assertion to precise outcomes or modifications in our expectations.

Supply hyperlink

Leave a Reply

Your email address will not be published.